Grants and Contributions:
Title:
Allowing gene correction therapy for sickle cell disease patients using advances in lipid nanoparticle formulation
Agreement Number:
1015395
Agreement Value:
$25,000.00
Agreement Date:
Mar 27, 2024 - Sep 30, 2025
Description:
Advances exploratory research under the New Beginnings Initiative
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators.
Location:
Ottawa, Ontario, CA K1G 4J5
Reference Number:
172-2023-2024-Q4-1015395
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
870157641
Recipient Type:
Not-for-profit organization or charity
Recipient's Legal Name:
Canadian Blood Services
Federal Riding Name:
Ottawa-Sud
Federal Riding Number:
35077
Program:
Collaborative Science, Technology and Innovation Program – Ideation Fund
Program Purpose:
The Ideation Fund is intended to encourage, test and validate transformative research ideas generated by teams of NRC scientific personnel and external collaborators with complementary capabilities, acting as a demonstration phase for a continually-evolving suite of research and development (R&D) deliverables at the NRC. The fund supports exploratory research through two mechanisms: the New Beginnings Initiative and the Small Teams Initiative.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences